Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Calgary

$34,900.00

Investigations on post-endoplasmic reticulum quality control mechanisms for prion protein aggregates

EF 2015-16

Résumé
Sustaining correct protein folding is critically important for cell survival and several neurodegenerative disorders are associated with the accumulation of misfolded proteins. Among these are prion diseases, which are fatal transmissible disorders of animals and humans. They are unique because they are caused by prions, pathogens which are composed solely of a misfolded isoform of the cellular prion protein PrPc, termed PrPSc. The long-term goals of my group are to elucidate mechanisms of neurodegeneration and to discover novel targets for inhibiting prion propagation and spreading by studying prion-host cell interactions and trafficking of prion proteins. One central question of my research program is how correct folding of PrPc is controlled within neuronal cells. PrPc is a glycoprotein located at the cell surface. Here, PrPc is found in lipid rafts, membrane microdomains with a high content of cholesterol and sphingolipids. Upon recycling and final internalization, PrPc is transported along the endocytic pathway for degradation in acidic vesicles. In mammalian cells, the best characterized protein quality control machinery resides in the endoplasmic reticulum (ER). However, what happens beyond the ER? Are there similar mechanisms existing that ensure protein quality control in post-ER compartments, such as the Golgi network? In my previously published work I described a novel post-ER quality control mechanism for PrPc. I demonstrated that treatment of cultured cells with the naphthyl-urea compound suramin induces PrPc aggregation. These aggregates are intracellulary retained and their transport to the cell surface is prevented. Instead, they are re-routed from the trans-Golgi network (TGN) to lysosomes for degradation. In contrast to pathogenic PrPSc aggregates, they are non-infectious and can be degraded by the cells with a half-life similar to that of PrPc. My further deletion mutant analysis revealed that re-routing, but not aggregation, is dependent on the presence of the pre-octarepeat domain (aa 23-50) of the PrP amino-terminus. Of note, similar observations were made by others for pathogenic PrP mutants. These mutants had a higher propensity to aggregate and were, as the drug-induced PrP aggregates described by myself, intracellularly re-routed to lysosomes for degradation. Furthermore, the protease furin is subjected to post-ER quality control upon aggregation, and aggregates are transported to lysosomes. This indicates that re-routing of protein aggregates from TGN to lysosomes is a cellular mechanism not only relevant for PrP trafficking. In contrast to the well investigated ER protein quality control mechanisms, only little is known about post-ER protein quality control in mammalian cells. The goal of my proposed studies is to use drug-induced PrP aggregates as a model to gain novel mechanistic insights into post-ER quality control in mammalian cells. This will be achieved by three specific aims: 1. to identify proteins that are involved in post-ER quality control by siRNA library screens 2. to analyse the role of glycosylation in recognition of PrP aggregates, and 3. to investigate PrP aggregation in non-drug treated neuronal cells. I expect to obtain new insights into so far under-investigated post-ER quality control mechanisms in mammalian cells. Results obtained from my study will advance the understanding of the cellular capacity to counteract protein misfolding not only of the prion protein, but also of other proteins travelling through the secretory pathway. In a long term, my fundamental research on protein misfolding will result in novel drug targets to improve protein folding which will inspire translational approaches by the applied health research industry.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2014-04839
Name nom
Gilch, Sabine
Department département
Veterinary Medicine, Faculty of
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
34900
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5109
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Intra-cellular targeting
Research subject fr
Cibles intra-cellulaires
Partie
2
Nb partie
5
Application title
Investigations on post-endoplasmic reticulum quality control mechanisms for prion protein aggregates
Keyword
NSERC
Application summary
Sustaining correct protein folding is critically important for cell survival and several neurodegenerative disorders are associated with the accumulation of misfolded proteins. Among these are prion diseases, which are fatal transmissible disorders of animals and humans. They are unique because they are caused by prions, pathogens which are composed solely of a misfolded isoform of the cellular prion protein PrPc, termed PrPSc. The long-term goals of my group are to elucidate mechanisms of neurodegeneration and to discover novel targets for inhibiting prion propagation and spreading by studying prion-host cell interactions and trafficking of prion proteins. One central question of my research program is how correct folding of PrPc is controlled within neuronal cells. PrPc is a glycoprotein located at the cell surface. Here, PrPc is found in lipid rafts, membrane microdomains with a high content of cholesterol and sphingolipids. Upon recycling and final internalization, PrPc is transported along the endocytic pathway for degradation in acidic vesicles. In mammalian cells, the best characterized protein quality control machinery resides in the endoplasmic reticulum (ER). However, what happens beyond the ER? Are there similar mechanisms existing that ensure protein quality control in post-ER compartments, such as the Golgi network? In my previously published work I described a novel post-ER quality control mechanism for PrPc. I demonstrated that treatment of cultured cells with the naphthyl-urea compound suramin induces PrPc aggregation. These aggregates are intracellulary retained and their transport to the cell surface is prevented. Instead, they are re-routed from the trans-Golgi network (TGN) to lysosomes for degradation. In contrast to pathogenic PrPSc aggregates, they are non-infectious and can be degraded by the cells with a half-life similar to that of PrPc. My further deletion mutant analysis revealed that re-routing, but not aggregation, is dependent on the presence of the pre-octarepeat domain (aa 23-50) of the PrP amino-terminus. Of note, similar observations were made by others for pathogenic PrP mutants. These mutants had a higher propensity to aggregate and were, as the drug-induced PrP aggregates described by myself, intracellularly re-routed to lysosomes for degradation. Furthermore, the protease furin is subjected to post-ER quality control upon aggregation, and aggregates are transported to lysosomes. This indicates that re-routing of protein aggregates from TGN to lysosomes is a cellular mechanism not only relevant for PrP trafficking. In contrast to the well investigated ER protein quality control mechanisms, only little is known about post-ER protein quality control in mammalian cells. The goal of my proposed studies is to use drug-induced PrP aggregates as a model to gain novel mechanistic insights into post-ER quality control in mammalian cells. This will be achieved by three specific aims: 1. to identify proteins that are involved in post-ER quality control by siRNA library screens 2. to analyse the role of glycosylation in recognition of PrP aggregates, and 3. to investigate PrP aggregation in non-drug treated neuronal cells. I expect to obtain new insights into so far under-investigated post-ER quality control mechanisms in mammalian cells. Results obtained from my study will advance the understanding of the cellular capacity to counteract protein misfolding not only of the prion protein, but also of other proteins travelling through the secretory pathway. In a long term, my fundamental research on protein misfolding will result in novel drug targets to improve protein folding which will inspire translational approaches by the applied health research industry.